Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-01-16
2007-01-16
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
10384369
ABSTRACT:
The invention relates to methods of treating and preventing disorders associated with elevated TNF-α and/or IL-1β by administering therapeutic amounts of stearidonic acid. Further provided are methods for down-regulating TNF-α and/or IL-1β and assays for determining the presence, absence, or quantity of TNF-α and/or IL-1β in a subject in conjunction with a regimen of stearidonic acid administration.
REFERENCES:
patent: 4681896 (1987-07-01), Horrobin
patent: 5130449 (1992-07-01), Lagarde et al.
patent: 5158975 (1992-10-01), Guichardant et al.
patent: 5178873 (1993-01-01), Horrobin et al.
patent: 5434183 (1995-07-01), Larsson-Backstrom
patent: 5683698 (1997-11-01), Chavali et al.
patent: 6326355 (2001-12-01), Abbruzzese et al.
patent: 6340485 (2002-01-01), Coupland et al.
patent: 197 57 414 (1999-01-01), None
patent: 0 347 056 (1989-12-01), None
patent: 0 460 848 (1991-12-01), None
patent: WO 99/42101 (1999-08-01), None
patent: WO 02/092779 (2002-11-01), None
Harrison's Principles of Internal Medicine, Isselbacher et al. (eds.), vols. 1-2, 13th edition, published 1994 by McGraw-Hill, Inc. pp. 1116, 1167, 1403, 1643, 1648 and 2379.
Ablumunits et al., “Islet T cells secreting IFN-γ in NOD mouse diabetes: arrest by p277 peptide treatment,”J. Autoimmun., 11:73-81, 1998.
Beisel, “Herman award lecture, 1995: infection-induced malnutrition—from cholera to cytokines,”Am. J. Clin. Nutr., 62:813-819, 1995.
Bruserud, “Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients,”Leukemia Res., 20:65-73, 1996.
Cerami et al., “Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor),”Immunol. Lett., 11:173-177, 1985.
Cominelli and Pizarro, “Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease,”Ailment Pharmacol. Ther., 10:49-53, 1996.
Fong et al., “Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia,”J. Exp. Med., 170:1627-1633, 1989.
Fong et al., “Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins,”Am. J. Physiol., 256:R659-R665, 1989.
Gruol et al., “Physiological and pathological roles of interleukin-6 in the central nervous system,”Molecular Neurobiology, 15:307-339, 1997.
Hotamisligil and Spiegelman, “Tumor necrosis factor alpha: a key component of the obesity-diabetes link,”Diabetes, 43(11):1271-1278, 1994.
Howells, “Cytokine networks in destructive periodontal disease,”Oral Dis., 1:266-270, 1995.
James et al., “Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids,”Am. J. Clin. Nutr., 77:1140-1145, 2003.
Janeway et al., In:Immunobiology—The Immune System in Health and Disease, 4thEdition, Elsevier Scinece Ltd/ Garland Publsihing, 1999.
Mantzioris et al., “Biochemical effects of a diet containing foods enriched with n-3 fatty acids,”Am. J. Clin. Nutr., 72:42-48, 2000.
Mantzioris et al., “Dietary substitution with an α-linolenic acid-rich vegetable oil increases eicosapentoaenoic acid concentrations in tissues,”Am. J. Clin. Nutr., 59:1304-1309, 1994.
McCarthy et al., “Suppression of food intake during infection: is interleukin-1 involved?”Am. J. Clin. Nutr., 42:1179-1182, 1985.
Moldawer et al., “Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines,”Am. J. Physiol., 254:G450-G456, 1988.
Moller, “Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes,”Trends Endocrinol Metab, 11(6):212-217, 2000.
Rankin et al., “The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis,”British J. Rheum., 34:334-342, 1995.
Ridker et al., “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,”New England Journal of Medicine, 342(12):836-843, 2000.
Simopoulos, “ω-3 fatty acids in the prevention-management of cardiovascular disease,”Can. J. Physiol. Pharmacol., 75:234-239, 1997.
Stack et al., “Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease,”Lancet, 349:521-524, 1997.
Caughey et al., “The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acides from vegetable oil or fish oil 1-3,”Am J. Clin. Nutr., 63:116-122, 1996.
Heesen et al., “IL-1ra serum levels in disease stages of ms—a marker for progression,”Acta Neurol Scand, 101:95-97, 2000.
James Michael J.
Ursin Virginia
Fulbright & Jaworski L.L.P.
Henley III Raymond J.
Monsanto Technology L.L.C.
Royal Adelaide Hospital
LandOfFree
Treatment and prevention of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of inflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776074